Inhibrx Biosciences Reports Topline Results From Registrational ChonDRAgon Study Investigating Ozekibart As Single Agent Vs. Placebo In Patients With Unresectable Chondrosarcoma; Ozekibart Meets Primary Endpoint In Chondrosarcoma

Author: Benzinga Newsdesk | October 23, 2025 03:20pm

• Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo 
• Key secondary endpoints reinforce the primary benefit, demonstrating meaningful improvements in disease control and patient quality of life
• Inhibrx plans to file a BLA in Q2 of 2026
• Interim data from expansion cohorts in patients with colorectal cancer and Ewing sarcoma demonstrate high response and disease control rates in difficult-to-treat, heavily pretreated patients
• Management to host conference call today at 1:30 p.m. Pacific Time, to review the topline results and ongoing cohorts

SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma.  The Company also provided updates on the ongoing expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma.

Posted In: INBX